An observational study in Chronic Myeloid Leukemia, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.
Sponsored by Bristol-Myers Squibb · Observational
This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 177 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
All French hematologists will be invited to participate to the study, and the study will be conducted by hematologists agreeing to participate. Each participating investigator will need to enroll consecutive CP-CML patients who meet the selection criteria.
Exclusion Criteria:
Other: Non-Interventional
Non-Interventional
Incidence of CP-CML patients remaining on dasatinib treatment
Time frame: 24 months
Distribution of median age of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of sex ratio of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of concomitant treatment of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of cardiovascular risk factors of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of body mass index (BMI) of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of comorbidities of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of disease characteristics duration between diagnosis and drug initiation in CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution disease characteristics of last known molecular response in CP-CML patients receiving dasatinib
Time frame: 24 months
SOKAL distribution of disease characteristics of CP-CML patients receiving dasatinib
Time frame: 24 months
Distribution of prior treatment(s) of CP-CML patients receiving dasatinib
Time frame: 24 months
Incidence of initiating dasatinib due to suboptimal response
Time frame: 24 months
Incidence of initiating dasatinib due to failure
Time frame: 24 months
Incidence of initiating dasatinib due to intolerance
Time frame: 24 months
Incidence of initiating dasatinib due to convenience
Time frame: 24 months
Incidence of initiating dasatinib due to physician decision
Time frame: 24 months
Incidence of AE's
Time frame: 24 months
Incidence of SAE's
Time frame: 24 months
Utilization of dasatinib
Time frame: 24 months
Incidence of complete molecular response (CMR)
Time frame: Up to 24 months
Incidence of major molecular response (MMR)
Time frame: Up to 24 months
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb